For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Infliximab - Pouchitis
PAD Profile : Infliximab - Pouchitis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Ankylosing spondylitis
- Inflammatory bowel disease
- Psoriasis
- Psoriatic arthritis
- Rheumatoid arthritis
- Immunotherapy related colitis
- Inflammatory bowel disease - paediatric use
- Uveitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Behcet's syndrome
Additional Documents
Committee Recommendations
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve infliximab for chronic pouchitis after treatment with steroids and/or antibiotics in combination.
Infliximab will be assigned a RED traffic light status on the Prescribing Advisory Database (PAD)
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”